Popular Articles

Drug Crimes In Canada Cause Continuing Problems For Small Communities
The Narconon drug rehab program has noticed a trend of many drug addicts being involved with drug related charges due to their addiction. "You can have the everyday functioning addict who is battling a drug addiction, and just one day gets caught by police for possession of a small amount," comments Nick Hayes, a representative of Narconon Trois-Rivieres. "This is an all too common situation for many people who are involved in a drug addiction." More people are using illicit drugs in Canada, in fact Trois-Rivieres, Quebec, Canada, where the Narconon drug rehab program is located, is one of the leading cities in Canada for drug crimes. "There are so many youth in Trois-Rivieres who are addicted to different drugs like speed, ecstasy, marijuana, and even cocaine. These teens get caught up with the law and start heading down the wrong path at a very young age," says Nick.

POZEN Submits New Drug Application For VIMOVO™ (PN 400)
POZEN Inc. (NASDAQ:POZN), announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the marketing approval of VIMOVO™ (PN 400), the combination of enteric coated (EC) naproxen and immediate release esomeprazole. POZEN and AstraZeneca entered into a global co-development agreement for VIMOVO in August 2006. Pending regulatory approval, the proposed trade name is VIMOVO and the proposed indications are for the signs and symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis in patients who are at risk for developing NSAID-associated ulcers.
News of the day
Bovie Medical Corporation Announces 510K Submission To The FDA For Its BOSS Soft Tissue Coagulation Device
Bovie Medical Corporation (the "Company") (NYSE-AMEX Symbol: BVX), a manufacturer and marketer of electrosurgical products, announced a 510K submission to the FDA seeking pre-market clearance for Bovie"s BOSS for surgical applications where soft tissue bipolar coagulation is desired. The BOSS is the latest generation device based on Bovie"s saline enhanced sintered steel technology.
Diagnostics

Can The Relationship Between Doctors And Drug Companies Ever Be A Healthy One?

Should the financial ties between doctors and drug companies be completely cut, or are healthy alliances between the two possible with the common aim of improving human health? A debate in this week"s PLoS Medicine discusses whether the influence of drug company money on doctors is always a corrupting one. The relationship between doctors and drug companies has been the subject of intense scrutiny in recent years, with some commentators arguing that the public health mission of doctors is incompatible with the pharmaceutical industry motive to maximize profits for shareholders. Emma D"Arcy - the co-founder of www.myphid.com, an international networking site that allows healthcare workers and the pharmaceutical industry to communicate in a transparent way - disagrees that relationship is fundamentally incompatible. She suggests that "authentic alliances" between doctors and the drug industry can be formed with the common aim of improving human health and safe and effective medicines. Pointing out that the drug industry remains an important of funding for scientific meetings and continuing medical education, she outlines three ways in which healthy collaboration can be encouraged without needing to further regulate the industry. These include: teaching medical professionals to distinguish between clinical information and promotional material; ensuring transparency from both parties through networking sites such as www.myphid.com; and encouraging industry and doctors to follow an "everyday credo" to make sure interactions ultimately benefit the care of people living with disease and further medical scientific understanding. Ray Moynihan of the University of Newcastle, New South Wales, Australia, argues that transparency is not enough to ensure that physicians" prescribing behaviour is not distorted by pharmaceutical influence. He cites evidence collected on the site of the non-profit group Healthy Skepticism (http://www.healthyskepticism.org), including a systematic review demonstrating that studies sponsored by pharmaceutical companies were more likely to have outcomes favouring their sponsor, and calls for the medical profession to disentangle itself completely from the money it accepts from the pharmaceutical industry. He highlights the case of pharmaceutical industry distortion of continuing medical education, in particular the ability of doctors to gain professional credits and company sponsored events. Giving examples of education for doctors in Australia where sponsors have even determined topics and speakers for seminars, he concludes that there should be a complete ban on all industry funding of continuing medical education, whether direct or indirect. Complete disentanglement is a healthier alternative, argues Moynihan, and strategies such as the American Medical Student Associations "PharmFree" campaign, which has advocated the severing of financial ties, prefigure "a future where fewer doctors will be prescribing under the influence of industry." Funding: ED received no specific funding to write this article. RM received a commissioning fee from PLoS to write his Viewpoint. Competing Interests: Emma Darcy is the co-founder of http://www.myphid.com, an international professional networking site for the pharmaceutical industry and the medical community. She has worked with many pharmaceutical companies, medical societies, and medical education communication companies and is a supporter of open and transparent interactions between all. Ray Moynihan has declared that he has no competing interests. Citation: "Can the Relationship between Doctors and Drug Companies Ever Be a Healthy One?" D"Arcy E, Moynihan R (2009) PLoS Med 6(7): e1000075. doi:10.1371/journal.pmed.1000075 PLoS Medicine


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):